Hikma Pharmaceuticals/£HIK
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About Hikma Pharmaceuticals
Hikma Pharmaceuticals is a multinational pharmaceutical company headquartered in London, United Kingdom. It specializes in the development, manufacturing, and marketing of a broad portfolio of branded and non-branded generic and in-licensed pharmaceutical products. The company operates across three main segments: Injectables, Generics, and Branded, serving hospitals, pharmacies, and wholesalers. Hikma was founded in 1978 in Amman, Jordan, and has since expanded its operations globally, maintaining a significant presence in the Middle East and North Africa, the United States, and Europe. Its strategic positioning is supported by its extensive manufacturing capabilities and a strong commitment to quality and regulatory compliance.
Ticker
£HIK
Sector
Primary listing
LSE
Employees
9,400
Headquarters
Website
HIK Metrics
BasicAdvanced
£3.1bn
10.86
£1.35
0.64
£0.62
4.21%
Price and volume
Market cap
£3.1bn
Beta
0.64
52-week high
£21.46
52-week low
£11.87
Average daily volume
830k
Dividend rate
£0.62
Financial strength
Current ratio
1.819
Quick ratio
0.91
Long term debt to equity
57.176
Total debt to equity
61.55
Dividend payout ratio (TTM)
46.02%
Interest coverage (TTM)
6.05%
Profitability
EBITDA (TTM)
629.185
Gross margin (TTM)
43.51%
Net profit margin (TTM)
12.00%
Operating margin (TTM)
19.35%
Effective tax rate (TTM)
21.58%
Revenue per employee (TTM)
£269,010
Management effectiveness
Return on assets (TTM)
7.50%
Return on equity (TTM)
16.52%
Valuation
Price to earnings (TTM)
10.861
Price to revenue (TTM)
1.295
Price to book
1.25
Price to tangible book (TTM)
2.26
Price to free cash flow (TTM)
36.441
Free cash flow yield (TTM)
2.74%
Free cash flow per share (TTM)
0.403
Dividend yield (TTM)
4.21%
Growth
Revenue change (TTM)
7.10%
Earnings per share change (TTM)
12.42%
3-year revenue growth (CAGR)
9.99%
10-year revenue growth (CAGR)
8.81%
3-year earnings per share growth (CAGR)
29.16%
10-year earnings per share growth (CAGR)
3.74%
3-year dividend per share growth (CAGR)
14.47%
10-year dividend per share growth (CAGR)
10.13%
What the Analysts think about HIK
Analyst ratings (Buy, Hold, Sell) for Hikma Pharmaceuticals stock.
HIK Financial Performance
Revenues and expenses
HIK Earnings Performance
Company profitability
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.
Capital at risk
Upcoming events
No upcoming events
FAQs